Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 739-742, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-922241
ABSTRACT
45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase inhibitor (TKI) therapy and chemotherapy, finding effective options for them is an unmet clinic need. Herein we reported a case that till January 12, 2021, an 82-year-old female with sensitizing EGFR-mutant advanced lung adenocarcinoma received a surprising progression-free survival (PFS) benefit of over 21 months from the combination therapy of pembrolizumab and anlotinib after her failure of treatments of osimertinib, chemotherapy and anlotinib-monotherapy.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quinolines
/
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoma, Non-Small-Cell Lung
/
Antibodies, Monoclonal, Humanized
/
ErbB Receptors
/
Adenocarcinoma of Lung
/
Indoles
/
Lung Neoplasms
/
Mutation
Limits:
Aged
/
Aged80
/
Female
/
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS